Please try another search
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Sten Nilsson | 75 | 2013 | Medical Advisor |
Peter Leander | 66 | 2012 | Medical Advisor |
Kari Gronas | 58 | 2018 | Independent Director |
Nicklas Westerholm | 47 | 2019 | Independent Director |
Alan Raffensperger | 63 | 2023 | Independent Director |
Per Hall | - | 2022 | Medical Advisor |
Hans Arwidsson | 65 | 2023 | Independent Chairman of the Board |
Kristian Pietras | - | 2023 | Medical Advisor |
Timothy Roberts | - | 2022 | Medical Advisor |
Austin Smith | - | 2023 | Medical Advisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review